AstraZeneca PLC (STO:AZN)
Sweden · Delayed Price · Currency is SEK | Market Cap | 2.89T +27.5% |
| Revenue (ttm) | 541.41B +8.6% |
| Net Income | 94.25B +45.3% |
| EPS | 60.28 +45.3% |
| Shares Out | n/a |
| PE Ratio | 30.61 |
| Forward PE | 19.58 |
| Dividend | 29.30 (1.54%) |
| Ex-Dividend Date | Feb 19, 2026 |
| Volume | 241,252 |
| Average Volume | 243,026 |
| Open | 1,860.00 |
| Previous Close | 1,859.50 |
| Day's Range | 1,848.00 - 1,869.00 |
| 52-Week Range | 1,252.00 - 1,925.50 |
| Beta | 0.28 |
| RSI | 57.18 |
| Earnings Date | Apr 29, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsNews
Only Two Days Away – Don't Miss it! C-Level Technology Leadership and the Rise of Iconic Leaders Will Shape the Conversation at HMG Strategy's 2026 New York Summit. Be a Part of It. Register Now.
FAIRFIELD, Conn., April 14, 2026 (GLOBE NEWSWIRE) -- HMG Strategy, the world's leading platform for inspiring technology executives to lead boldly and shape the future of business, will bring Big Appl...
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative 'personalized off-the-shelf' immunotherapy toward clinical development
Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard's lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that trigger...
Trump policies, China's biotech boom are ending Europe's pharma powerhouse era
Once the go-to location for global drugmakers, Europe is losing market share to aggressive U.S. trade policies and China's growth as a biotech hub. Europe's share of global R&D has been cut in half ov...
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
Parnassus Value Equity Fund's Strategic Moves: AstraZeneca PLC Takes Center Stage
The Zacks Analyst Blog Highlights AstraZeneca, HSBC, Walt Disney, Oak Valley Bancorp and BV Financial
AstraZeneca (AZN) leads Zacks Research highlights with strong drug growth and pipeline momentum, while HSBC and Disney navigate costs and competition.
Top Research Reports for AstraZeneca, HSBC & Walt Disney
AstraZeneca's strong drug portfolio and pipeline fuel growth targets, while HSBC restructures and Disney balances streaming gains against rising costs.
AstraZeneca, Telangana govt to roll out AI-powered lung cancer screening in public hospitals
Hyderabad: AstraZeneca Pharma India, a subsidiary of British-Swedish pharma giant AstraZeneca Plc, has signed a memorandum of understanding with the T.
Swiss industry body says US tariffs on pharmaceuticals will harm patients
U.S. President Donald Trump's 100% tariffs on the pharmaceutical industry threaten global production, supply chains and ultimately will harm patients, Switzerland's pharmaceutical association interph...
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all.
Trump threatens 100% tariff on US drug makers that don't strike deals to lower prices
New tax will hit branded drugs and active ingredients while exempting generics for at least one year
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import Duties
AstraZeneca (AZN) Faces New Tariff Challenges Amid U.S. Import Duties
Drugmakers face 100% tariff unless they cut prices or produce drugs in US
The Trump administration said on Thursday it will impose 100% tariffs on branded pharmaceuticals imported into the United States unless manufacturers agree to government drug pricing deals or commit ...
Global pharma companies that have publicly announced Trump drug pricing agreements
U.S. President Donald Trump secured agreements with 16 major pharmaceutical companies to bring U.S. prescription drug prices in line with those paid in other developed nations in exchange for three-ye...
AstraZeneca (AZN) Sees Success in EMERALD-3 Trial for Liver Cancer Treatment
AstraZeneca (AZN) Sees Success in EMERALD-3 Trial for Liver Cancer Treatment
AstraZeneca (AZN) Avoids Tariffs with Increased U.S. Commitment
AstraZeneca (AZN) Avoids Tariffs with Increased U.S. Commitment
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial
AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a common liver cancer lived before their disease worsen...
Trump Administration Prepares 100% Tariffs On Drugmakers Without Pricing Deals: Report
The Trump administration is reportedly preparing to announce 100% tariffs on pharmaceutical companies that have not secured pricing deals with the White House . The announcement could come as soon as ...
AstraZeneca: Imfinzi, Imjudo Combo With Lenvatinib And TACE Show Positive Phase III Trial Results
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) announced Thursday positive high-level results from its EMERALD-3 Phase III trial of Imfinzi (durvalumab) in combination with Imjudo (tremel...
AstraZeneca Scores Pediatric Win While Adult Trial Falls Short In Rare Bone Disease
AstraZeneca reports mixed Phase 3 data for efzimfotase alfa in HPP and positive COPD results for tozorakimab; shares rise on updates. ... Full story available on Benzinga.com
AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results
The company said the results support the drug's potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible.
AstraZeneca: Efzimfotase Alfa Shows Positive Results From Phase III Programme
(RTTNews) - AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) said the efzimfotase alfa or ALXN1850 Phase III clinical programme, designed to study a broad hypophosphatasia patient population, demonstrated pos...
If You Invested $1000 In AstraZeneca Stock 10 Years Ago, You Would Have This Much Today
AstraZeneca (NYSE: AZN) has outperformed the market over the past 10 years by 1.12% on an annualized basis producing an average annual return of 13.13%. Currently, AstraZeneca has a market capitaliza...
AstraZeneca stock jumps as COPD drug trial win surprises market
Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its experimental chronic obstructive pulmonary disease (COPD) treatment, tozorakim...
AstraZeneca Stock Rises 4% Over Positive Data From Tozorakimab Study
(RTTNews) - Shares of AstraZeneca PLC (AZN) are gaining about 4 percent on Friday morning trading after the company announced positive high-level results from the Phase III OBERON and TITANIA trials i...